The aging brain undergoes structural and cellular changes that can impact function and increase susceptibility to neurodegenerative disorders like Alzheimer’s disease.
RNAi Win in ATTR-CM; HF Congestion Monitor Approved; Lp(a) & In-Stent Restenosis
Vutrisiran (Amvuttra), an RNA-interfering (RNAi) therapy, reduced hard events and disease progression in transthyretin amyloidosis cardiomyopathy (ATTR-CM) regardless of background tafamidis (Vyndamax, Vyndaqel) therapy, according